Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs) (RDAD)

14 septembre 2017 mis à jour par: Linda Teri, University of Washington

From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services

The University of Washington's Northwest Research Group on Aging is partnering with Area Agencies on Aging (AAA) in Washington and Oregon to complete this translational investigation of RDAD (Reducing Disabilities in Alzheimer's Disease). RDAD is an evidence-based program with demonstrated efficacy in helping older adults with dementia maintain physical function and remain physically and mentally healthy. This study asks two questions: 1) Can AAA partners successfully translate and implement RDAD, and 2) Is AAA implementation of RDAD effective in producing desired outcomes among agencies, providers, and older adults with dementia and their family members. This study is being conducted in Washington and Oregon states.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

510

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • États-Unis
    • Washington
      • Seattle, Washington, États-Unis, 98195
        • University of Washington

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

65 ans et plus (Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Care Recipients must

  • Have a diagnosis of dementia
  • Be 65 years of age or older
  • Currently exercise no more than 150 minutes a week and not regularly participate in a formal exercise program.

Caregivers must

  • Live in the community
  • Provide care to the care recipient with dementia

Exclusion Criteria:

Either Care-recipient or Caregiver must not

  • Plan to move to a long-term residential care setting within 6 months of enrollment.
  • Plan to move from the study geographic area within 4 months of enrollment.
  • Have a known terminal illness (with death anticipated within the next 12 months)
  • Have had a hospitalization for a psychiatric disorder in the 12 months prior to baseline
  • Be actively suicidal, hallucinating, or delusional
  • Be blind, deaf, or not ambulatory

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Autre: RDAD
Exercise training for caregiver and care recipient. Behavior modification training for caregiver.
Comportemental: RDAD
Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Minutes of exercise per week
Délai: Change from baseline in number of minutes of exercise each week during treatment phase of study, weeks 7-12
Caregivers will track the number of minutes per week the care recipients engage in exercise recommended by the coach.
Change from baseline in number of minutes of exercise each week during treatment phase of study, weeks 7-12
Restricted Activity Days
Délai: Baseline
Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.
Baseline
Restricted Activity Days
Délai: Change from Baseline to Pre-Treatment (6 weeks)
Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.
Change from Baseline to Pre-Treatment (6 weeks)
Restricted Activity Days
Délai: Change from Baseline to Post- Treatment 1 (13 weeks)
Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.
Change from Baseline to Post- Treatment 1 (13 weeks)
Restricted Activity Days
Délai: Change from Baseline to Post-Treatment 2 (30 weeks)
Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.
Change from Baseline to Post-Treatment 2 (30 weeks)
Restricted Days of Activity
Délai: Change from Baseline to 13 Month Follow-Up
Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.
Change from Baseline to 13 Month Follow-Up
Independence/Residential Status
Délai: Change from Baseline to 13 Month Follow-Up
All participants will be in independent living situations at baseline. Any move from independent living to a care facility will be documented throughout the 13 month study.
Change from Baseline to 13 Month Follow-Up

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Revised Memory and Behavior Problem Checklist (RMBPC)
Délai: Baseline
Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.
Baseline
Revised Memory and Behavior Problem Checklist (RMBPC)
Délai: Change from Baseline to Pre-Treatment (6 weeks)
Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.
Change from Baseline to Pre-Treatment (6 weeks)
Revised Memory and Behavior Problem Checklist (RMBPC)
Délai: Change from Baseline to Post-Treatment 1 (13 weeks)
Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.
Change from Baseline to Post-Treatment 1 (13 weeks)
Revised Memory and Behavior Problem Checklist (RMBPC)
Délai: Change from Baseline to Post-Treatment 2 (30 weeks)
Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.
Change from Baseline to Post-Treatment 2 (30 weeks)
Revised Memory and Behavior Problem Checklist (RMBPC)
Délai: Change from Baseline to 13 Month Follow-Up
Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.
Change from Baseline to 13 Month Follow-Up
Quality of Life-AD
Délai: Baseline
This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.
Baseline
Quality of Life-AD
Délai: Change from Baseline to Pre-Treatment (6 weeks)
This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.
Change from Baseline to Pre-Treatment (6 weeks)
Quality of Life-AD
Délai: Change from Baseline to Post-Treatment 1 (13 weeks)
This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.
Change from Baseline to Post-Treatment 1 (13 weeks)
Quality of Life-AD
Délai: Change from Baseline to Post-Treatment 2 (30 weeks)
This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.
Change from Baseline to Post-Treatment 2 (30 weeks)
Quality of Life-AD
Délai: Change from Baseline to 13 Month Follow-Up
This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.
Change from Baseline to 13 Month Follow-Up
CES-D
Délai: Baseline
This 20-item scale that assesses depression in caregivers.
Baseline
CES-D
Délai: Change from Baseline to Pre-Treatment (6 weeks)
A 20-item scale that assesses depression in caregivers.
Change from Baseline to Pre-Treatment (6 weeks)
CES-D
Délai: Change from Baseline to Post-Treatment 1 (13 weeks)
A 20-item scale that assesses depression in caregivers.
Change from Baseline to Post-Treatment 1 (13 weeks)
CES-D
Délai: Change from Baseline to Post-Treatment 2 (30 weeks)
A 20-item scale that assesses depression in caregivers.
Change from Baseline to Post-Treatment 2 (30 weeks)
CES-D
Délai: Change from Baseline to 13 Month Follow-Up
A 20-item scale that assesses depression in caregivers.
Change from Baseline to 13 Month Follow-Up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

University of Washington

Les enquêteurs

  • Chercheur principal: Linda Teri, Ph.D., University of Washington

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 novembre 2012

Achèvement primaire (Réel)

1 juin 2017

Achèvement de l'étude (Réel)

1 juin 2017

Dates d'inscription aux études

Première soumission

9 octobre 2012

Première soumission répondant aux critères de contrôle qualité

15 octobre 2012

Première publication (Estimation)

16 octobre 2012

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

15 septembre 2017

Dernière mise à jour soumise répondant aux critères de contrôle qualité

14 septembre 2017

Dernière vérification

1 septembre 2017

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 41906

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner